30 results about "Nkg2d receptor" patented technology

Multi-specific binding proteins that bind NKG2D receptor, CD16, and a tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1 are described, as well pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

The invention discloses a chimeric antigen receptor targeting HER2 and co-expressing PD1-MICA fusion protein as well as its expression vector and application, which belong to the field of tumor immunity drugs. The chimeric antigen receptor includes: sequentially linked signal peptide, single-chain antibody targeting HER2, CD8α hinge region and transmembrane region, co-stimulatory factor, intracellular signal peptide, P2A linking peptide, IL2 signal peptide, PD1 cell Extracellular domain and MICA extracellular domain. The chimeric antigen receptor secretes PD1-MICA fusion protein while specifically targeting HER2-positive tumor cells, targets PD-L1 / PD-L2 positive tumor cells, and blocks PD1 and PD-L1 / PD-L1 of T cells L2 inhibits the signal, and at the same time, the extracellular region of MICA can bind to the NKG2D receptor to activate NK cells, so as to realize the purpose of CAR-T cells to effectively kill HER2-positive tumor cells in vivo.